| 1 |
Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009;497-506.
|
| 2 |
Won YW, Kwon JH, Lee SI, et al. Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL). Ann Hematol 2011, http://dx.doi.org/ 10.1007/s00277-011-1297-x.
|
| 3 |
Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients: international Hodgkin's Disease Collaborative Group. J Clin Oncol 1998;16:830-843.
|
| 4 |
Oza AM, Ganesan TS, Leahy M, et al. Patterns of survival in patients with Hodgkin's disease: long follow up in a single centre. Ann Oncol 1993;4:385-392.
|
| 5 |
Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1484.
DOI
ScienceOn
|
| 6 |
Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011;117:4208-4217.
DOI
ScienceOn
|
| 7 |
Blum KA. Upcoming diagnostic and therapeutic developments in classical Hodgkin's lymphoma. Hematology Am Soc Hematol Educ Program 2010;2010:93-100.
DOI
ScienceOn
|
| 8 |
Moskowitz A, Hamlin P, Gerecitano J, et al. Bendamustine is highly active in heavily pre-treated relapsed and refractory Hodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant [Abstract]. Blood 2009;114:A720.
|
| 9 |
Josting A, Nogova L, Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005;23:1522-1529.
DOI
ScienceOn
|
| 10 |
Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97: 616-623.
DOI
ScienceOn
|
| 11 |
Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051-1054.
DOI
ScienceOn
|
| 12 |
Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065-2071.
DOI
ScienceOn
|
| 13 |
Josting A, Muller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 2010;28:5074-5080.
DOI
ScienceOn
|
| 14 |
Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005;16:116-123.
DOI
ScienceOn
|
| 15 |
Akpek G, Ambinder RF, Piantadosi S, et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001;19:4314-4321.
|
| 16 |
Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry: Societe Française de Greffe de Moélle. Bone Marrow Transplant 1997; 20:21-26.
DOI
ScienceOn
|
| 17 |
Fung HC, Stiff P, Schriber J, et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant 2007;13:594-600.
DOI
ScienceOn
|
| 18 |
Smith SM, van Besien K, Carreras J, et al. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant 2008;14: 904-912.
DOI
ScienceOn
|
| 19 |
Gajewski JL, Phillips GL, Sobocinski KA, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996;14:572-578.
|
| 20 |
Peggs KS, Sureda A, Qian W, et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007;139:70-80.
DOI
ScienceOn
|
| 21 |
Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:455-462.
DOI
ScienceOn
|
| 22 |
Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Mills GB, Younes A. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol 2006;132:503-511.
|
| 23 |
Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning (RIC-allo) in patients with relapsed or refractory Hodgkin's lymphoma (HL): final analysis of the HDR-allo protocol- A prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante Autologo de Medula Osea (GEL/TAMO) and the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation [Abstract]. Blood 2009;114:A658.
|
| 24 |
Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146: 171-179.
DOI
ScienceOn
|
| 25 |
Fanale M, Fayad L, Pro B, et al. Phase I study of bortezomib in combination with ICE (BICE) in patients with relapsed/refractory classical Hodgkin lymphoma [Abstract]. Blood 2008;112:A3048.
DOI
ScienceOn
|
| 26 |
Johnston PB, Ansell SM, Colgan JP, et al. mTOR inhibition for relapsed or refractory Hodgkin lymphoma: promising single agent activity with everolimus (RAD001) [Abstract]. Blood 2007; 110:A753.
|
| 27 |
Kirschbaum MH, Goldman BH, Zain JM, et al. Vorinostat (suberoylanilide hydroxamic acid) in relapsed or refractory Hodgkin lymphoma: SWOG 0517 [Abstract]. Blood 2007; 110:A759.
|
| 28 |
Younes A, Ong TC, Ribrag V, et al. Efficacy of panobinostat in phase II study in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplat [Abstract]. Blood 2009;114:A923.
|
| 29 |
Younes A, Pro B, Fanale M, et al. Isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin lymphoma (HL) [Abstract]. Blood 2007;110:A2566.
|
| 30 |
Younes A, Pro B, Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 2006;107:1731-1732.
DOI
ScienceOn
|
| 31 |
Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875-885.
DOI
ScienceOn
|
| 32 |
Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma 2007;48:1313-1319.
DOI
ScienceOn
|
| 33 |
Fanale M, Fayad L, Pro B, et al. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol 2011;154:284-286.
DOI
ScienceOn
|
| 34 |
Kelley TW, Pohlman B, Elson P, Hsi ED. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007;128:958-965.
DOI
ScienceOn
|
| 35 |
Kuruvilla J, Taylor D, Wang L, et al. Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma [Abstract]. Blood 2008;112:A3052.
DOI
ScienceOn
|
| 36 |
Jones RJ, Gocke CD, Kasamon YL, et al. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood 2009;113:5920-5926.
DOI
ScienceOn
|
| 37 |
Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003;98:310-314.
DOI
ScienceOn
|
| 38 |
Ambinder RF. Epstein-barr virus and hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2007;204-209.
|
| 39 |
Bollard CM, Cooper LJ, Heslop HE. Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol 2008;21:405-420.
DOI
ScienceOn
|
| 40 |
Roskrow MA, Rooney CM, Heslop HE, et al. Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Hum Gene Ther 1998;9:1237-1250.
DOI
ScienceOn
|
| 41 |
Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigenpresenting cells and T-lymphocyte transfer. Blood 2007;110:2838-2845.
DOI
ScienceOn
|
| 42 |
Lucas KG, Salzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer 2004;100:1892-1901.
DOI
ScienceOn
|
webmaster
